Ab-initio pharma | Formulation and GMP product manufacturing services for clinical trials in Australia

Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.

The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.

Outcomes (FY2020): 

  • Facility has been designed
  • The build is beginning and installation of machinery planned for FY2021.

Visit The University of Sydney for more information.

    Twitter: Sydney_Uni

    LinkedIn: The University of Sydney

    Consortium leadThe University of Sydney
    Consortium membersAb Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia
    MTPConnect grant$500,000
    Industry contribution$500,000
    Project durationJune 2018 - June 2021
    ContactPaul Young, The University of Sydney - paul.young@sydney.edu.au